Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Prior to Limited Chemotherapy as Front-Line Therapy for Classical Hodgkin Lymphoma
NCT06164275Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in classic Hodgkin lymphoma (cHL), sponsored by Northwestern University. Started Feb 2024; status: active, not recruiting.
02
Drugs
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06164275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164275.